(S)-MK-26

-MK-26 is an atypical dopamine reuptake inhibitor that was derived from modafinil. It is closely related to two other modafinil analogues, (S,''S)-CE-158 and (S'')-CE-123.
-MK-26 has markedly improved potency and selectivity as a blocker of the dopamine transporter compared to modafinil.
It has pro-motivational effects in animals and reverses tetrabenazine-induced motivational deficits and depression-like behavior. The drug dose-dependently increases extracellular dopamine levels in the nucleus accumbens and prefrontal cortex, does not modify locomotor activity, and slightly enhances spatial memory in animals.
There has been interest in -MK-26 as a potential treatment for depression, psychostimulant use disorder, Alzheimer's disease, and aging-related disorders. It was first described by 2022.